Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Financial Officer

President and CEO

Vice President of Finance

Chief Executive Officer

President and COO

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of avutometinib and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-05	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-25	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-20	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2024-03-19	Premium	sold	Premium	Premium	Premium	-
2024-03-19	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-19	Premium	sold	Premium	Premium	Premium	-
2024-03-18	Premium	sold	Premium	Premium	Premium	-
2024-03-18	Premium	sold	Premium	Premium	Premium	President and CEO
2024-03-18	Premium	sold	Premium	Premium	Premium	-
2024-02-06	Premium	sold	Premium	Premium	Premium	-
2024-01-12	Premium	sold	Premium	Premium	Premium	-
2024-01-05	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-26	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-20	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2023-12-19	Premium	sold	Premium	Premium	Premium	President and CEO
2023-12-19	Premium	sold	Premium	Premium	Premium	-
2023-12-19	Premium	sold	Premium	Premium	Premium	-
2023-12-18	Premium	sold	Premium	Premium	Premium	-
2023-12-18	Premium	sold	Premium	Premium	Premium	-
2023-12-18	Premium	sold	Premium	Premium	Premium	President and CEO
2023-10-05	Premium	sold	Premium	Premium	Premium	Vice President of Finance
2023-09-25	Premium	sold	Premium	Premium	Premium	Vice President of Finance
2023-09-21	Premium	sold	Premium	Premium	Premium	Vice President of Finance
2023-09-19	Premium	sold	Premium	Premium	Premium	President and CEO
2023-09-19	Premium	sold	Premium	Premium	Premium	-

VSTM - Verastem Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for VSTM